Alzheimer's therapy targeting the β-secretase enzyme BACE1: Benefits and potential limitations from the perspective of animal model studies

Brain Research Bulletin

Volumn 126, Issue , 2016, Pages 183-198

  Ohno, Masuo ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; BACE1; Learning and memory; Mouse model; Synaptic function; Secretase

Indexed keywords

5,6 DIHYDRO 2 IMINO 3 METHYL 6 [4 [5 (1 PROPYNYL) 3 PYRIDINYL] 2 THIENYL] 4 PYRIMIDINONE; ASPARTIC PROTEINASE INHIBITOR; AZD 3293; BETA SECRETASE 1; E 2609; GRL 8234; LY 2811376; LY 2886721; SCH 1682496; TAK 070; UNCLASSIFIED DRUG; [OM 00 3] DR 9; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; SECRETASE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; HAPLOINSUFFICIENCY; HUMAN; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REVIEW; SPATIAL LEARNING; SPATIAL MEMORY; TREATMENT DURATION; WORKING MEMORY; ANIMAL; DISEASE MODEL; ENZYMOLOGY; GENE THERAPY; GENETICS; METABOLISM; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; HUMANS; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS;

EID: 84965146157     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2016.04.007     Document Type: Review

References (195)

1. Abramov, E., Dolev, I., Fogel, H., Ciccotosto, G.D., Ruff, E., Slutsky, I., Amyloid-β as a positive endogenous regulator of release probability at hippocampal synapses. Nat. Neurosci. 12 (2009), 1567–1576.
2. Atwal, J.K., Chen, Y., Chiu, C., Mortensen, D.L., Meilandt, W.J., Liu, Y., Heise, C.E., Hoyte, K., Luk, W., Lu, Y., et al. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci. Transl. Med., 3, 2011, 84ra43.
3. Barao, S., Moechars, D., Lichtenthaler, S.F., De Strooper, B., BACE1 physiological functions may limit its use as therapeutic target for Alzheimer's disease. Trends Neurosci. 39 (2016), 158–169.
4. Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., Marcus, D.S., Cairns, N.J., Xie, X., Blazey, T.M., et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. New Engl. J. Med. 367 (2012), 795–804.
5. Battaglia, F., Wang, H.Y., Ghilardi, M.F., Gashi, E., Quartarone, A., Friedman, E., Nixon, R.A., Cortical plasticity in Alzheimer's disease in humans and rodents. Biol. Psychiatry 62 (2007), 1405–1412.
6. Belyaev, N.D., Kellett, K.A., Beckett, C., Makova, N.Z., Revett, T.J., Nalivaeva, N.N., Hooper, N.M., Turner, A.J., The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a β-secretase-dependent pathway. J. Biol. Chem. 285 (2010), 41443–41454.
7. Ben Halima, S., Mishra, S., Raja, K.M., Willem, M., Baici, A., Simons, K., Brustle, O., Koch, P., Haass, C., Caflisch, A., Rajendran, L., Specific inhibition of β-secretase processing of the Alzheimer disease amyloid precursor protein. Cell Rep. 14 (2016), 2127–2141.
8. Berger-Sweeney, J., McPhie, D.L., Arters, J.A., Greenan, J., Oster-Granite, M.L., Neve, R.L., Impairments in learning and memory accompanied by neurodegeneration in mice transgenic for the carboxyl-terminus of the amyloid precursor protein. Brain Res. Mol. Brain Res. 66 (1999), 150–162.
9. Busche, M.A., Eichhoff, G., Adelsberger, H., Abramowski, D., Wiederhold, K.H., Haass, C., Staufenbiel, M., Konnerth, A., Garaschuk, O., Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 321 (2008), 1686–1689.
10. Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D.R., Price, D.L., Wong, P.C., BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nat. Neurosci. 4 (2001), 233–234.
11. Cai, J., Qi, X., Kociok, N., Skosyrski, S., Emilio, A., Ruan, Q., Han, S., Liu, L., Chen, Z., Bowes Rickman, C., et al. β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol. Med. 4 (2012), 980–991.
12. Cataldo, A.M., Peterhoff, C.M., Troncoso, J.C., Gomez-Isla, T., Hyman, B.T., Nixon, R.A., Endocytic pathway abnormalities precede amyloid β deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 157 (2000), 277–286.
13. Chami, L., Checler, F., BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer's disease. Mol. Neurodegener., 7, 2012, 52.
14. Chang, R.C., Wong, A.K., Ng, H.K., Hugon, J., Phosphorylation of eukaryotic initiation factor-2α (eIF2α) is associated with neuronal degeneration in Alzheimer's disease. Neuroreport 13 (2002), 2429–2432.
15. Chang, W.P., Koelsch, G., Wong, S., Downs, D., Da, H., Weerasena, V., Gordon, B., Devasamudram, T., Bilcer, G., Ghosh, A.K., Tang, J., In vivo inhibition of Aβ production by memapsin 2 (β-secretase) inhibitors. J. Neurochem. 89 (2004), 1409–1416.
16. Chang, W.P., Downs, D., Huang, X.P., Da, H., Fung, K.M., Tang, J., Amyloid-β reduction by memapsin 2 (β-secretase) immunization. FASEB J. 21 (2007), 3184–3196.
17. Chang, W.P., Huang, X., Downs, D., Cirrito, J.R., Koelsch, G., Holtzman, D.M., Ghosh, A.K., Tang, J., β-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J. 25 (2011), 775–784.
18. Chang, X., Rong, C., Chen, Y., Yang, C., Hu, Q., Mo, Y., Zhang, C., Gu, X., Zhang, L., He, W., et al. (-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression. Exp. Cell Res. 334 (2015), 136–145.
19. Chen, R., Zhang, J., Wu, Y., Wang, D., Feng, G., Tang, Y.P., Teng, Z., Chen, C., Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. Cell Rep. 2 (2012), 1329–1339.
20. Cheret, C., Willem, M., Fricker, F.R., Wende, H., Wulf-Goldenberg, A., Tahirovic, S., Nave, K.A., Saftig, P., Haass, C., Garratt, A.N., et al. Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles. EMBO J. 32 (2013), 2015–2028.
21. Choi, S.H., Park, C.H., Koo, J.W., Seo, J.H., Kim, H.S., Jeong, S.J., Lee, J.H., Kim, S.S., Suh, Y.H., Memory impairment and cholinergic dysfunction by centrally administered Aβ and carboxyl-terminal fragment of Alzheimer's APP in mice. FASEB J. 15 (2001), 1816–1818.
22. Chow, V.W., Savonenko, A.V., Melnikova, T., Kim, H., Price, D.L., Li, T., Wong, P.C., Modeling an anti-amyloid combination therapy for Alzheimer's disease. Sci. Transl. Med., 2, 2010, 13ra11.
23. Citron, M., Diehl, T.S., Capell, A., Haass, C., Teplow, D.B., Selkoe, D.J., Inhibition of amyloid β-protein production in neural cells by the serine protease inhibitor AEBSF. Neuron 17 (1996), 171–179.
24. Colombo, A., Wang, H., Kuhn, P.H., Page, R., Kremmer, E., Dempsey, P.J., Crawford, H.C., Lichtenthaler, S.F., Constitutive α- and β-secretase cleavages of the amyloid precursor protein are partially coupled in neurons, but not in frequently used cell lines. Neurobiol. Dis. 49 (2013), 137–147.
25. Corbett, B.F., Leiser, S.C., Ling, H.P., Nagy, R., Breysse, N., Zhang, X., Hazra, A., Brown, J.T., Randall, A.D., Wood, A., et al. Sodium channel cleavage is associated with aberrant neuronal activity and cognitive deficits in a mouse model of Alzheimer's disease. J. Neurosci. 33 (2013), 7020–7026.
26. Dawson, G.R., Seabrook, G.R., Zheng, H., Smith, D.W., Graham, S., O'Dowd, G., Bowery, B.J., Boyce, S., Trumbauer, M.E., Chen, H.Y., et al. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the β-amyloid precursor protein. Neuroscience 90 (1999), 1–13.
27. De Strooper, B., Simons, M., Multhaup, G., Van Leuven, F., Beyreuther, K., Dotti, C.G., Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. EMBO J. 14 (1995), 4932–4938.
28. De Strooper, B., Vassar, R., Golde, T., The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 6 (2010), 99–107.
29. DeMattos, R., May, P., Racke, M., Hole, J., Tzaferis, J., Liu, F., DeLong, C., Day, T., Yang, Z., Boggs, L., et al. Combination therapy with a plaque-specific Abeta antibody and BACE inhibitor results in dramatic plaque lowering in aged PDAPP transgenic mice. Alzheimers Dement., 10(Suppl. 4), 2014, P149.
30. Devi, L., Ohno, M., Genetic reductions of β-site amyloid precursor protein-cleaving enzyme 1 and amyloid-β ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer's disease model mice. Eur. J. Neurosci. 31 (2010), 110–118.
31. Devi, L., Ohno, M., Phospho-eIF2α level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory defects in 5XFAD mice. PLoS One, 5, 2010, e12974.
32. Devi, L., Ohno, M., Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice. Neurobiol. Dis. 45 (2012), 417–424.
33. Devi, L., Ohno, M., Deletion of the eIF2α kinase GCN2 fails to rescue the memory decline associated with Alzheimer's disease. PLoS One, 8, 2013, e77335.
34. Devi, L., Ohno, M., Mechanisms that lessen benefits of β-secretase reduction in a mouse model of Alzheimer's disease. Transl. Psychiatry, 3, 2013, e284.
35. Devi, L., Ohno, M., PERK mediates elF2α phosphorylation responsible for BACE1 elevation, CREB dysfunction and neurodegeneration in a mouse model of Alzheimer's disease. Neurobiol. Aging 35 (2014), 2272–2281.
36. Devi, L., Ohno, M., A combination Alzheimer's therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice. Mol. Brain, 8, 2015, 19.
37. Devi, L., Ohno, M., Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stages. Neuroscience 307 (2015), 128–137.
38. Devi, L., Ohno, M., TrkB reduction exacerbates Alzheimer's disease-like signaling aberrations and memory deficits without affecting β-amyloidosis in 5XFAD mice. Transl. Psychiatry, 5, 2015, e562.
39. Devi, L., Alldred, M.J., Ginsberg, S.D., Ohno, M., Sex- and brain region-specific acceleration of β-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease. Mol. Brain, 3, 2010, 34.
40. Devi, L., Alldred, M.J., Ginsberg, S.D., Ohno, M., Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer's disease. PLoS One, 7, 2012, e32792.
41. Devi, L., Tang, J., Ohno, M., Beneficial effects of the β-secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression. Curr. Alzheimer Res. 12 (2015), 13–21.
42. Dominguez, D., Tournoy, J., Hartmann, D., Huth, T., Cryns, K., Deforce, S., Serneels, L., Camacho, I.E., Marjaux, E., Craessaerts, K., et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J. Biol. Chem. 280 (2005), 30797–30806.
43. Eriksen, J.L., Janus, C.G., Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav. Genet. 37 (2007), 79–100.
44. Farris, W., Schutz, S.G., Cirrito, J.R., Shankar, G.M., Sun, X., George, A., Leissring, M.A., Walsh, D.M., Qiu, W.Q., Holtzman, D.M., Selkoe, D.J., Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am. J. Pathol. 171 (2007), 241–251.
45. Filser, S., Ovsepian, S.V., Masana, M., Blazquez-Llorca, L., Brandt Elvang, A., Volbracht, C., Muller, M.B., Jung, C.K., Herms, J., Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. Biol. Psychiatry 77 (2015), 729–739.
46. Flammang, B., Pardossi-Piquard, R., Sevalle, J., Debayle, D., Dabert-Gay, A.S., Thevenet, A., Lauritzen, I., Checler, F., Evidence that the amyloid-β protein precursor intracellular domain, AICD, derives from β-secretase-generated C-terminal fragment. J. Alzheimers Dis. 30 (2012), 145–153.
47. Frankland, P.W., Bontempi, B., The organization of recent and remote memories. Nat. Rev. Neurosci. 6 (2005), 119–130.
48. Frankland, P.W., O'Brien, C., Ohno, M., Kirkwood, A., Silva, A.J., α-CaMKII-dependent plasticity in the cortex is required for permanent memory. Nature 411 (2001), 309–313.
49. Frisardi, V., Solfrizzi, V., Imbimbo, P.B., Capurso, C., D'Introno, A., Colacicco, A.M., Vendemiale, G., Seripa, D., Pilotto, A., Capurso, A., Panza, F., Towards disease-modifying treatment of Alzheimer's disease: drugs targeting β-amyloid. Curr. Alzheimer Res. 7 (2010), 40–55.
50. Fukumoto, H., Cheung, B.S., Hyman, B.T., Irizarry, M.C., β-Secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch. Neurol. 59 (2002), 1381–1389.
51. Fukumoto, H., Rosene, D.L., Moss, M.B., Raju, S., Hyman, B.T., Irizarry, M.C., β-Secretase activity increases with aging in human, monkey, and mouse brain. Am. J. Pathol. 164 (2004), 719–725.
52. Fukumoto, H., Takahashi, H., Tarui, N., Matsui, J., Tomita, T., Hirode, M., Sagayama, M., Maeda, R., Kawamoto, M., Hirai, K., et al. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Aβ pathology and behavioral deficits in a mouse model of Alzheimer's disease. J. Neurosci. 30 (2010), 11157–11166.
53. Garcia-Osta, A., Alberini, C.M., Amyloid beta mediates memory formation. Learn. Mem. 16 (2009), 267–272.
54. Ghosal, K., Vogt, D.L., Liang, M., Shen, Y., Lamb, B.T., Pimplikar, S.W., 2009: Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 18367–18372.
55. Ghosh, A.K., Osswald, H.L., BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease. Chem. Soc. Rev. 43 (2014), 6765–6813.
56. Ghosh, A.K., Kumaragurubaran, N., Hong, L., Koelsh, G., Tang, J., Memapsin 2 (beta-secretase) inhibitors: drug development. Curr. Alzheimer Res. 5 (2008), 121–131.
57. Ginsberg, S.D., Alldred, M.J., Counts, S.E., Cataldo, A.M., Neve, R.L., Jiang, Y., Wuu, J., Chao, M.V., Mufson, E.J., Nixon, R.A., Che, S., Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol. Psychiatry 68 (2010), 885–893.
58. Goodger, Z.V., Rajendran, L., Trutzel, A., Kohli, B.M., Nitsch, R.M., Konietzko, U., Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway. J. Cell Sci. 122 (2009), 3703–3714.
59. +-ATPase inhibitor bafilomycin A1 differentially affects proteolytic processing of mutant and wild-type β-amyloid precursor protein. J. Biol. Chem. 270 (1995), 6186–6192.
60. Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
61. Hemming, M.L., Elias, J.E., Gygi, S.P., Selkoe, D.J., Identification of β-secretase (BACE1) substrates using quantitative proteomics. PLoS One, 4, 2009, e8477.
62. Hersh, L.B., Rodgers, D.W., Neprilysin and amyloid β peptide degradation. Curr. Alzheimer Res. 5 (2008), 225–231.
63. Hessler, S., Zheng, F., Hartmann, S., Rittger, A., Lehnert, S., Volkel, M., Nissen, M., Edelmann, E., Saftig, P., Schwake, M., et al. β-Secretase BACE1 regulates hippocampal and reconstituted M-currents in a β-subunit-like fashion. J. Neurosci. 35 (2015), 3298–3311.
64. –/–mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. Mol. Neurodegener., 5, 2010, 31.
65. Holsinger, R.M., McLean, C.A., Beyreuther, K., Masters, C.L., Evin, G., Increased expression of the amyloid precursor β-secretase in Alzheimer's disease. Ann. Neurol. 51 (2002), 783–786.
66. Hongpaisan, J., Sun, M.K., Alkon, D.L., PKC ε activation prevents synaptic loss, Aβ elevation, and cognitive deficits in Alzheimer's disease transgenic mice. J. Neurosci. 31 (2011), 630–643.
67. Hook, V., Toneff, T., Bogyo, M., Greenbaum, D., Medzihradszky, K.F., Neveu, J., Lane, W., Hook, G., Reisine, T., Inhibition of cathepsin B reduces β-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate β-secretase of Alzheimer's disease. Biol. Chem. 386 (2005), 931–940.
68. Hook, V., Schechter, I., Demuth, H.U., Hook, G., Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease. Biol. Chem. 389 (2008), 993–1006.
69. Hu, X., Hicks, C.W., He, W., Wong, P., Macklin, W.B., Trapp, B.D., Yan, R., Bace1 modulates myelination in the central and peripheral nervous system. Nat. Neurosci. 9 (2006), 1520–1525.
70. Hu, X., Zhou, X., He, W., Yang, J., Xiong, W., Wong, P., Wilson, C.G., Yan, R., BACE1 deficiency causes altered neuronal activity and neurodegeneration. J. Neurosci. 30 (2010), 8819–8829.
71. Hu, X., He, W., Luo, X., Tsubota, K.E., Yan, R., BACE1 regulates hippocampal astrogenesis via the Jagged1-Notch pathway. Cell Rep. 4 (2013), 40–49.
72. Huang, S.M., Mouri, A., Kokubo, H., Nakajima, R., Suemoto, T., Higuchi, M., Staufenbiel, M., Noda, Y., Yamaguchi, H., Nabeshima, T., et al. Neprilysin-sensitive synapse-associated amyloid-β peptide oligomers impair neuronal plasticity and cognitive function. J. Biol. Chem. 281 (2006), 17941–17951.
73. Hussain, I., Powell, D., Howlett, D.R., Tew, D.G., Meek, T.D., Chapman, C., Gloger, I.S., Murphy, K.E., Southan, C.D., Ryan, D.M., et al. Identification of a novel aspartic protease (Asp 2) as β-secretase. Mol. Cell. Neurosci. 14 (1999), 419–427.
74. Ittner, L.M., Gotz, J., Amyloid-β and tau −a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 12 (2011), 65–72.
75. Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.J., Hama, E., Sekine-Aizawa, Y., Saido, T.C., Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6 (2000), 143–150.
76. Iwata, N., Takaki, Y., Fukami, S., Tsubuki, S., Saido, T.C., Region-specific reduction of Aβ-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J. Neurosci. Res. 70 (2002), 493–500.
77. Jack, C.R. Jr., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., Petersen, R.C., Trojanowski, J.Q., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9 (2010), 119–128.
78. Jacobsen, J.S., Wu, C.C., Redwine, J.M., Comery, T.A., Arias, R., Bowlby, M., Martone, R., Morrison, J.H., Pangalos, M.N., Reinhart, P.H., Bloom, F.E., Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 5161–5166.
79. London mice. J. Neurosci. 34 (2014), 11621–11630.
80. Jankowsky, J.L., Slunt, H.H., Gonzales, V., Savonenko, A.V., Wen, J.C., Jenkins, N.A., Copeland, N.G., Younkin, L.H., Lester, H.A., Younkin, S.G., Borchelt, D.R., Persistent amyloidosis following suppression of Aβ production in a transgenic model of Alzheimer disease. PLoS Med., 2, 2005, e355.
81. Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T.A., Wirths, O., Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol. Aging 33 (2012), 196.e129–196.e140.
82. Jiang, Y., Mullaney, K.A., Peterhoff, C.M., Che, S., Schmidt, S.D., Boyer-Boiteau, A., Ginsberg, S.D., Cataldo, A.M., Mathews, P.M., Nixon, R.A., Alzheimer's-related endosome dysfunction in Down syndrome is Aβ-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 1630–1635.
83. Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488 (2012), 96–99.
84. Kandalepas, P.C., Sadleir, K.R., Eimer, W.A., Zhao, J., Nicholson, D.A., Vassar, R., The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol. 126 (2013), 329–352.
85. Kim, D.Y., Carey, B.W., Wang, H., Ingano, L.A., Binshtok, A.M., Wertz, M.H., Pettingell, W.H., He, P., Lee, V.M., Woolf, C.J., Kovacs, D.M., BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat. Cell Biol. 9 (2007), 755–764.
86. v1: 1 levels in BACE1-null mice. J. Biol. Chem 286 (2011), 8106–8116.
87. Kimura, R., Ohno, M., Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol. Dis. 33 (2009), 229–235.
88. Kimura, R., Devi, L., Ohno, M., Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice. J. Neurochem. 113 (2010), 248–261.
89. Kitazume, S., Nakagawa, K., Oka, R., Tachida, Y., Ogawa, K., Luo, Y., Citron, M., Shitara, H., Taya, C., Yonekawa, H., et al. In vivo cleavage of α2,6-sialyltransferase by Alzheimer β-secretase. J. Biol. Chem. 280 (2005), 8589–8595.
90. Kitazume, S., Oka, R., Ogawa, K., Futakawa, S., Hagiwara, Y., Takikawa, H., Kato, M., Kasahara, A., Miyoshi, E., Taniguchi, N., Hashimoto, Y., Molecular insights into β-galactoside α2,6-sialyltransferase secretion in vivo. Glycobiology 19 (2009), 479–487.
91. Klein, C., Mathis, C., Leva, G., Patte-Mensah, C., Cassel, J.C., Maitre, M., Mensah-Nyagan, A.G., γ-Hydroxybutyrate (Xyrem) ameliorates clinical symptoms and neuropathology in a mouse model of Alzheimer's disease. Neurobiol. Aging 36 (2015), 832–844.
92. Kuhn, P.H., Koroniak, K., Hogl, S., Colombo, A., Zeitschel, U., Willem, M., Volbracht, C., Schepers, U., Imhof, A., Hoffmeister, A., et al. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J. 31 (2012), 3157–3168.
93. LaFerla, F.M., Oddo, S., Alzheimer's disease Aβ, tau and synaptic dysfunction. Trends Mol. Med. 11 (2005), 170–176.
94. Lahiri, D.K., Maloney, B., Long, J.M., Greig, N.H., Lessons from a BACE1 inhibitor trial: off-site but not off base. Alzheimers Dement. 10 (2014), S411–S419.
95. Laird, F.M., Cai, H., Savonenko, A.V., Farah, M.H., He, K., Melnikova, T., Wen, H., Chiang, H.C., Xu, G., Koliatsos, V.E., et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-β amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 25 (2005), 11693–11709.
96. Lauritzen, I., Pardossi-Piquard, R., Bauer, C., Brigham, E., Abraham, J.D., Ranaldi, S., Fraser, P., St-George-Hyslop, P., Le Thuc, O., Espin, V., et al. The β-secretase-derived C-terminal fragment of βAPP C99, but not Aβ, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J. Neurosci. 32 (2012), 16243–16255a.
97. Lee, K.W., Im, J.Y., Song, J.S., Lee, S.H., Lee, H.J., Ha, H.Y., Koh, J.Y., Gwag, B.J., Yang, S.D., Paik, S.G., Han, P.L., Progressive neuronal loss and behavioral impairments of transgenic C57BL/6 inbred mice expressing the carboxy terminus of amyloid precursor protein. Neurobiol. Dis. 22 (2006), 10–24.
98. Lesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M., Ashe, K.H., A specific amyloid-β protein assembly in the brain impairs memory. Nature 440 (2006), 352–357.
99. Lewerenz, J., Maher, P., Basal levels of eIF2α phosphorylation determine cellular antioxidant status by regulating ATF4 and xCT expression. J. Biol. Chem. 284 (2009), 1106–1115.
100. Li, H., Guo, Q., Inoue, T., Polito, V.A., Tabuchi, K., Hammer, R.E., Pautler, R.G., Taffet, G.E., Zheng, H., Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow. Mol. Neurodegener., 9, 2014, 28.
101. Li, S., Hou, H., Mori, T., Sawmiller, D., Smith, A., Tian, J., Wang, Y., Giunta, B., Sanberg, P.R., Zhang, S., Tan, J., Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice. Sci. Rep., 5, 2015, 11322.
102. Lichtenthaler, S.F., Dominguez, D.I., Westmeyer, G.G., Reiss, K., Haass, C., Saftig, P., De Strooper, B., Seed, B., The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J. Biol. Chem. 278 (2003), 48713–48719.
103. Lin, X., Koelsch, G., Wu, S., Downs, D., Dashti, A., Tang, J., Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 1456–1460.
104. Lin, H.B., Yang, X.M., Li, T.J., Cheng, Y.F., Zhang, H.T., Xu, J.P., Memory deficits and neurochemical changes induced by C-reactive protein in rats: implication in Alzheimer's disease. Psychopharmacology 204 (2009), 705–714.
105. Luo, X., Yan, R., Inhibition of BACE1 for therapeutic use in Alzheimer's disease. Int. J. Clin. Exp. Pathol. 3 (2010), 618–628.
106. Luo, Y., Bolon, B., Kahn, S., Bennett, B.D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., et al. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat. Neurosci. 4 (2001), 231–232.
107. Luo, Y., Bolon, B., Damore, M.A., Fitzpatrick, D., Liu, H., Zhang, J., Yan, Q., Vassar, R., Citron, M., BACE1 (β-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol. Dis. 14 (2003), 81–88.
108. Ma, H., Lesne, S., Kotilinek, L., Steidl-Nichols, J.V., Sherman, M., Younkin, L., Younkin, S., Forster, C., Sergeant, N., Delacourte, A., et al. Involvement of β-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 8167–8172.
109. Ma, T., Trinh, M.A., Wexler, A.J., Bourbon, C., Gatti, E., Pierre, P., Cavener, D.R., Klann, E., Suppression of eIF2α kinases alleviates Alzheimer's disease-related plasticity and memory deficits. Nat. Neurosci. 16 (2013), 1299–1305.
110. Manczak, M., Reddy, P.H., Abnormal interaction of oligomeric amyloid-β with phosphorylated tau: implications to synaptic dysfunction and neuronal damage. J. Alzheimers Dis. 36 (2013), 285–295.
111. Mawuenyega, K.G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J.C., Yarasheski, K.E., Bateman, R.J., Decreased clearance of CNS β-amyloid in Alzheimer's disease. Science, 330, 2010, 1774.
112. May, P.C., Dean, R.A., Lowe, S.L., Martenyi, F., Sheehan, S.M., Boggs, L.N., Monk, S.A., Mathes, B.M., Mergott, D.J., Watson, B.M., et al. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J. Neurosci. 31 (2011), 16507–16516.
113. McConlogue, L., Buttini, M., Anderson, J.P., Brigham, E.F., Chen, K.S., Freedman, S.B., Games, D., Johnson-Wood, K., Lee, M., Zeller, M., et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J. Biol. Chem. 282 (2007), 26326–26334.
114. McGowan, E., Eriksen, J., Hutton, M., A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 22 (2006), 281–289.
115. Minkeviciene, R., Rheims, S., Dobszay, M.B., Zilberter, M., Hartikainen, J., Fulop, L., Penke, B., Zilberter, Y., Harkany, T., Pitkanen, A., Tanila, H., Amyloid β-induced neuronal hyperexcitability triggers progressive epilepsy. J. Neurosci. 29 (2009), 3453–3462.
116. Moreno, J.A., Halliday, M., Molloy, C., Radford, H., Verity, N., Axten, J.M., Ortori, C.A., Willis, A.E., Fischer, P.M., Barrett, D.A., Mallucci, G.R., Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci. Transl. Med., 5, 2013, 206ra138.
117. Morley, J.E., Farr, S.A., Banks, W.A., Johnson, S.N., Yamada, K.A., Xu, L., A physiological role for amyloid-β protein:enhancement of learning and memory. J. Alzheimers Dis. 19 (2010), 441–449.
118. Mouton-Liger, F., Paquet, C., Dumurgier, J., Bouras, C., Pradier, L., Gray, F., Hugon, J., Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2α pathway. Biochim. Biophys. Acta 1822 (2012), 885–896.
119. Nalbantoglu, J., Tirado-Santiago, G., Lahsaini, A., Poirier, J., Goncalves, O., Verge, G., Momoli, F., Welner, S.A., Massicotte, G., Julien, J.P., Shapiro, M.L., Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature 387 (1997), 500–505.
120. Nalivaeva, N.N., Belyaev, N.D., Lewis, D.I., Pickles, A.R., Makova, N.Z., Bagrova, D.I., Dubrovskaya, N.M., Plesneva, S.A., Zhuravin, I.A., Turner, A.J., Effect of sodium valproate administration on brain neprilysin expression and memory in rats. J. Mol. Neurosci. 46 (2012), 569–577.
121. Nishitomi, K., Sakaguchi, G., Horikoshi, Y., Gray, A.J., Maeda, M., Hirata-Fukae, C., Becker, A.G., Hosono, M., Sakaguchi, I., Minami, S.S., et al. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J. Neurochem. 99 (2006), 1555–1563.
122. O'Connor, T., Sadleir, K.R., Maus, E., Velliquette, R.A., Zhao, J., Cole, S.L., Eimer, W.A., Hitt, B., Bembinster, L.A., Lammich, S., et al. Phosphorylation of the translation initiation factor eIF2α increases BACE1 levels and promotes amyloidogenesis. Neuron 60 (2008), 988–1009.
123. Oakley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26 (2006), 10129–10140.
124. Ohno, M., Sametsky, E.A., Younkin, L.H., Oakley, H., Younkin, S.G., Citron, M., Vassar, R., Disterhoft, J.F., BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41 (2004), 27–33.
125. Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W.L., Vassar, R., Disterhoft, J.F., Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur. J. Neurosci. 23 (2006), 251–260.
126. Ohno, M., Cole, S.L., Yasvoina, M., Zhao, J., Citron, M., Berry, R., Disterhoft, J.F., Vassar, R., BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol. Dis. 26 (2007), 134–145.
127. Ohno, M., Genetic and pharmacological basis for therapeutic inhibition of β- and γ-secretases in mouse models of Alzheimer's memory deficits. Rev. Neurosci. 17 (2006), 429–454.
128. Ohno, M., β-Secretase as a prime therapeutic target for Alzheimer's disease: a perspective from mouse model studies. Araki, W., (eds.) Recent Advances in the Biology of Secretases, Key Proteases in Alzheimer's Disease, 2008, Research Signpost, Kerala, India, 1–25.
129. Ohno, M., Failures to reconsolidate memory in a mouse model of Alzheimer's disease. Neurobiol. Learn. Mem. 92 (2009), 455–459.
130. Ohno, M., Impaired memory mechanisms in mouse models of Alzheimer's disease. Giese, K.P., (eds.) Memory Mechanisms in Health and Diseases: Mechanistic Basis of Memory, 2012, World Scientific Publishing, London, UK, 343–379.
131. Ohno, M., Roles of eIF2α kinases in the pathogenesis of Alzheimer's disease. Front. Mol. Neurosci., 7, 2014, 22.
132. Oster-Granite, M.L., McPhie, D.L., Greenan, J., Neve, R.L., Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J. Neurosci. 16 (1996), 6732–6741.
133. Palop, J.J., Mucke, L., Amyloid-β-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 13 (2010), 812–818.
134. Palop, J.J., Chin, J., Roberson, E.D., Wang, J., Thwin, M.T., Bien-Ly, N., Yoo, J., Ho, K.O., Yu, G.Q., Kreitzer, A., et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55 (2007), 697–711.
135. Pastorino, L., Ikin, A.F., Lamprianou, S., Vacaresse, N., Revelli, J.P., Platt, K., Paganetti, P., Mathews, P.M., Harroch, S., Buxbaum, J.D., BACE (β-secretase) modulates the processing of APLP2 in vivo. Mol. Cell. Neurosci. 25 (2004), 642–649.
136. Perrin, R.J., Fagan, A.M., Holtzman, D.M., Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461 (2009), 916–922.
137. Puzzo, D., Privitera, L., Leznik, E., Fa, M., Staniszewski, A., Palmeri, A., Arancio, O., Picomolar amyloid-β positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 28 (2008), 14537–14545.
138. Puzzo, D., Privitera, L., Fa, M., Staniszewski, A., Hashimoto, G., Aziz, F., Sakurai, M., Ribe, E.M., Troy, C.M., Mercken, M., et al. Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann. Neurol. 69 (2011), 819–830.
139. Puzzo, D., Privitera, L., Palmeri, A., Hormetic effect of amyloid-beta peptide in synaptic plasticity and memory. Neurobiol. Aging 33 (2012), 1484.e1415–1484.e1424.
140. Qi, Y., Klyubin, I., Harney, S.C., Hu, N., Cullen, W.K., Grant, M.K., Steffen, J., Wilson, E.N., Do Carmo, S., Remy, S., et al. Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Aβ-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: rapid reversal by anti-Aβ agents. Acta Neuropathol. Commun., 2, 2014, 175.
141. Rabe, S., Reichwald, J., Ammaturo, D., de Strooper, B., Saftig, P., Neumann, U., Staufenbiel, M., The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing. J. Neurochem. 119 (2011), 231–239.
142. Rabinovich-Nikitin, I., Rakover, I.S., Becker, M., Solomon, B., Beneficial effect of antibodies against β-secretase cleavage site of APP on Alzheimer's-like pathology in triple-transgenic mice. PLoS One, 7, 2012, e46650.
143. Radford, H., Moreno, J.A., Verity, N., Halliday, M., Mallucci, G.R., PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia. Acta Neuropathol. 130 (2015), 633–642.
144. Rajapaksha, T.W., Eimer, W.A., Bozza, T.C., Vassar, R., The Alzheimer's β-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb. Mol. Neurodegener., 6, 2011, 88.
145. Rajendran, L., Annaert, W., Membrane trafficking pathways in Alzheimer's disease. Traffic 13 (2012), 759–770.
146. Rakover, I., Arbel, M., Solomon, B., Immunotherapy against APP β-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain Aβ levels. Neurodegener. Dis. 4 (2007), 392–402.
147. Reilly, C.E., Neprilysin content is reduced in Alzheimer brain areas. J. Neurol. 248 (2001), 159–160.
148. Roberds, S.L., Anderson, J., Basi, G., Bienkowski, M.J., Branstetter, D.G., Chen, K.S., Freedman, S.B., Frigon, N.L., Games, D., Hu, K., et al. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10 (2001), 1317–1324.
149. Rockenstein, E., Mante, M., Alford, M., Adame, A., Crews, L., Hashimoto, M., Esposito, L., Mucke, L., Masliah, E., High β-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-β levels: implications for the treatment of Alzheimer disease. J. Biol. Chem. 280 (2005), 32957–32967.
150. Rossner, S., Sastre, M., Bourne, K., Lichtenthaler, S.F., Transcriptional and translational regulation of BACE1 expression–implications for Alzheimer's disease. Prog. Neurobiol. 79 (2006), 95–111.
151. Sadleir, K.R., Eimer, W.A., Kaufman, R.J., Osten, P., Vassar, R., Genetic inhibition of phosphorylation of the translation initiation factor eIF2α does not block Aβ-dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease. PLoS One, 9, 2014, e101643.
152. Saido, T.C., Leissring, M.A., Proteolytic degradation of amyloid-β protein. Selkoe, D.J., Mandelkow, E., Holtzman, D.M., (eds.) In The Biology of Alzheimer Disease, 2012, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA, 387–404.
153. Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., Saido, T.C., Single App knock-in mouse models of Alzheimer's disease. Nat. Neurosci. 17 (2014), 661–663.
154. Sankaranarayanan, S., Price, E.A., Wu, G., Crouthamel, M.C., Shi, X.P., Tugusheva, K., Tyler, K.X., Kahana, J., Ellis, J., Jin, L., et al. In vivo β-secretase 1 inhibition leads to brain Aβ lowering and increased α-secretase processing of amyloid precursor protein without effect on neuregulin-1. J. Pharmacol. Exp. Ther. 324 (2008), 957–969.
155. Savonenko, A.V., Melnikova, T., Laird, F.M., Stewart, K.A., Price, D.L., Wong, P.C., Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 5585–5590.
156. Selkoe, D.J., Alzheimer's disease is a synaptic failure. Science 298 (2002), 789–791.
157. Seo, J., Giusti-Rodriguez, P., Zhou, Y., Rudenko, A., Cho, S., Ota, K.T., Park, C., Patzke, H., Madabhushi, R., Pan, L., et al. Activity-dependent p25 generation regulates synaptic plasticity and Aβ-induced cognitive impairment. Cell 157 (2014), 486–498.
158. Shyam, R., Ren, Y., Lee, J., Braunstein, K.E., Mao, H.Q., Wong, P.C., Intraventricular delivery of siRNA nanoparticles to the central nervous system. Mol. Ther. Nucleic Acids, 4, 2015, e242.
159. Singer, O., Marr, R.A., Rockenstein, E., Crews, L., Coufal, N.G., Gage, F.H., Verma, I.M., Masliah, E., Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 8 (2005), 1343–1349.
160. Sinha, S., Anderson, J.P., Barbour, R., Basi, G.S., Caccavello, R., Davis, D., Doan, M., Dovey, H.F., Frigon, N., Hong, J., et al. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 402 (1999), 537–540.
161. Solas, M., Aisa, B., Mugueta, M.C., Del Rio, J., Tordera, R.M., Ramirez, M.J., Interactions between age, stress and insulin on cognition: implications for Alzheimer's disease. Neuropsychopharmacology 35 (2010), 1664–1673.
162. Song, D.K., Won, M.H., Jung, J.S., Lee, J.C., Kang, T.C., Suh, H.W., Huh, S.O., Paek, S.H., Kim, Y.H., Kim, S.H., Suh, Y.H., Behavioral and neuropathologic changes induced by central injection of carboxyl-terminal fragment of β-amyloid precursor protein in mice. J. Neurochem. 71 (1998), 875–878.
163. Squire, L.R., Memory and the hippocampus: a synthesis from findings with rats monkeys, and humans. Psychol. Rev. 99 (1992), 195–231.
164. Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., Brynjolfsson, J., Gunnarsdottir, S., Ivarsson, O., Chou, T.T., et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71 (2002), 877–892.
165. Stromberg, K., Eketjall, S., Georgievska, B., Tunblad, K., Eliason, K., Olsson, F., Radesater, A.C., Klintenberg, R., Arvidsson, P.I., von Berg, S., et al. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production. FEBS J. 282 (2015), 65–73.
166. Stutzer, I., Selevsek, N., Esterhazy, D., Schmidt, A., Aebersold, R., Stoffel, M., Systematic proteomic analysis identifies β-site amyloid precursor protein cleaving enzyme 2 and 1 (BACE2 and BACE1) substrates in pancreatic β-cells. J. Biol. Chem. 288 (2013), 10536–10547.
167. Tamayev, R., Matsuda, S., Arancio, O., D'Adamio, L., β- but not γ-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. EMBO Mol. Med. 4 (2012), 171–179.
168. Thakker, D.R., Sankaranarayanan, S., Weatherspoon, M.R., Harrison, J., Pierdomenico, M., Heisel, J.M., Thompson, L.A., Haskell, R., Grace, J.E., Taylor, S.J., et al. Centrally delivered BACE1 inhibitor activates microglia, and reverses amyloid pathology and cognitive deficit in aged Tg2576 mice. J. Neurosci. 35 (2015), 6931–6936.
169. Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., Ross, S., Amarante, P., Loeloff, R., et al. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286 (1999), 735–741.
170. Vassar, R., Kuhn, P.H., Haass, C., Kennedy, M.E., Rajendran, L., Wong, P.C., Lichtenthaler, S.F., Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J. Neurochem. 130 (2014), 4–28.
171. Vassar, R., BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res. Ther., 6, 2014, 89.
172. Verret, L., Mann, E.O., Hang, G.B., Barth, A.M., Cobos, I., Ho, K., Devidze, N., Masliah, E., Kreitzer, A.C., Mody, I., et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149 (2012), 708–721.
173. von Arnim, C.A., Kinoshita, A., Peltan, I.D., Tangredi, M.M., Herl, L., Lee, B.M., Spoelgen, R., Hshieh, T.T., Ranganathan, S., Battey, F.D., et al. The low density lipoprotein receptor-related protein (LRP) is a novel β-secretase (BACE1) substrate. J. Biol. Chem. 280 (2005), 17777–17785.
174. Wang, L., Zang, Y., He, Y., Liang, M., Zhang, X., Tian, L., Wu, T., Jiang, T., Li, K., Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI. Neuroimage 31 (2006), 496–504.
175. Wang, H., Song, L., Laird, F., Wong, P.C., Lee, H.K., BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. J. Neurosci. 28 (2008), 8677–8681.
176. Wang, S., Wang, R., Chen, L., Bennett, D.A., Dickson, D.W., Wang, D.S., Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. J. Neurochem. 115 (2010), 47–57.
177. Wang, H., Li, R., Shen, Y., β-Secretase: its biology as a therapeutic target in diseases. Trends Pharmacol. Sci. 34 (2013), 215–225.
178. Wang, W., Liu, Y., Lazarus, R.A., Allosteric inhibition of BACE1 by an exosite-binding antibody. Curr. Opin. Struct. Biol. 23 (2013), 797–805.
179. Wang, H., Megill, A., Wong, P.C., Kirkwood, A., Lee, H.K., Postsynaptic target specific synaptic dysfunctions in the CA3 area of BACE1 knockout mice. PLoS One, 9, 2014, e92279.
180. Webster, S.J., Bachstetter, A.D., Van Eldik, L.J., Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease. Alzheimers Res. Ther., 5, 2013, 28.
181. Willem, M., Garratt, A.N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., Destrooper, B., Saftig, P., Birchmeier, C., Haass, C., Control of peripheral nerve myelination by the β-secretase BACE1. Science 314 (2006), 664–666.
182. Willem, M., Tahirovic, S., Busche, M.A., Ovsepian, S.V., Chafai, M., Kootar, S., Hornburg, D., Evans, L.D., Moore, S., Daria, A., et al. η-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature 526 (2015), 443–447.
183. Wong, H.K., Sakurai, T., Oyama, F., Kaneko, K., Wada, K., Miyazaki, H., Kurosawa, M., De Strooper, B., Saftig, P., Nukina, N., β Subunits of voltage-gated sodium channels are novel substrates of β-site amyloid precursor protein-cleaving enzyme (BACE1) and γ-secretase. J. Biol. Chem. 280 (2005), 23009–23017.
184. Yan, R., Vassar, R., Targeting the β secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 13 (2014), 319–329.
185. Yan, R., Bienkowski, M.J., Shuck, M.E., Miao, H., Tory, M.C., Pauley, A.M., Brashier, J.R., Stratman, N.C., Mathews, W.R., Buhl, A.E., et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity. Nature 402 (1999), 533–537.
186. Yang, L.B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X.L., Beach, T., Sue, L., Wong, P., Price, D., et al. Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 9 (2003), 3–4.
187. Yasojima, K., Akiyama, H., McGeer, E.G., McGeer, P.L., Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide. Neurosci. Lett. 297 (2001), 97–100.
188. Yu, Y.J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J.M., Prabhu, S., Watts, R.J., Dennis, M.S., Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med., 3, 2011, 84ra44.
189. Yu, Y.J., Atwal, J.K., Zhang, Y., Tong, R.K., Wildsmith, K.R., Tan, C., Bien-Ly, N., Hersom, M., Maloney, J.A., Meilandt, W.J., et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci. Transl. Med., 6, 2014, 261ra154.
190. Zhang, X.-M., Cai, Y., Xiong, K., Cai, H., Luo, X.-G., Feng, J.-C., Clough, R.W., Struble, R.G., Patrylo, P.R., Yan, X.-X., β-Secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. Eur. J. Neurosci. 30 (2009), 2271–2283.
191. Zhang, Z., Liu, X., Schroeder, J.P., Chan, C.B., Song, M., Yu, S.P., Weinshenker, D., Ye, K., 7,8-Dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 39 (2014), 638–650.
192. Zhang, Z., Song, M., Liu, X., Su Kang, S., Duong, D.M., Seyfried, N.T., Cao, X., Cheng, L., Sun, Y.E., Yu, S. Ping, et al. Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer's disease. Nat. Commun., 6, 2015, 8762.
193. Zhao, J., Fu, Y., Yasvoina, M., Shao, P., Hitt, B., O'Connor, T., Logan, S., Maus, E., Citron, M., Berry, R., et al. β-Site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J. Neurosci. 27 (2007), 3639–3649.
194. Zhou, L., Chavez-Gutierrez, L., Bockstael, K., Sannerud, R., Annaert, W., May, P.C., Karran, E., De Strooper, B., Inhibition of β-secretase in vivo via antibody binding to unique loops (D and F) of BACE1. J. Biol. Chem. 286 (2011), 8677–8687.
195. Zhou, L., Barao, S., Laga, M., Bockstael, K., Borgers, M., Gijsen, H., Annaert, W., Moechars, D., Mercken, M., Gevaert, K., De Strooper, B., The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo. J. Biol. Chem. 287 (2012), 25927–25940.